About us

CBD Solutions was founded in 2013 with the goal to find a cure for the disease Corticobasal Degeneration (CBD). The lack of research and diagnostic methods has made this a challenging task, but at CBD Solutions we are determined to provide the best conditions for scientists and medical professionals alike to work together and solve the mystery.

We are entirely financed by the founder’s, Sten Mörtstedt, charitable trust, which allows us to focus all our efforts on working in collaboration with world leading scientists, with patient groups, charities and the pharmaceutical industry towards our goal. Our goal to assemble the best researchers in the field, to fund and support their work and ultimately find a treatment for the disease.

Board of directors

Sten Mortstedt (Chairman)
Sten Mortstedt, a businessman and philanthropist, has a consistent track record during a period of over 40 years, of building profitable and sustainable businesses. He currently serves as Executive Chairman of CLS Holdings plc, a pan-European property company which he established in 1987 and took to a listing on the main market of the London Stock Exchange in 1994. In addition to his focus on property, he has been commercially active in a number of investment areas outside the property arena and has seen a number of the companies in which he has invested through to successful stock exchange listings or trade sales.

Björn Bloth (Vice Chairman)
Björn Bloth, MD, PhD, Associated Professor, works as scientific and medical advisor to several foundations and organisations. He has a PhD in Medical microbiology and immunology and has also a board certification in Internal medicine. He has been practicing medicine for many years.

Ingvar Dahlqvist (member)
Ingvar Dahlqvist has a BA in economy. He has for several years worked in Europe for a French industrial group as a Business Controller and Financial Director, for market development and as a Managing Director and is today a member and a chairman of the board of a number of Swedish and French companies. He is also the chairman of the Parkinson association in the south of Sweden and also a member of the election committee of the national Parkinson association in Sweden.

Angela Crawley (member)
Angela Crawley has a BA in Psychology and a MA in Psychotherapy. She has a private practice in the London area.

Anna Seeley (member)
Anna Seeley (née Mortstedt) is a qualified Chartered Surveyor and has worked in the property industry for over 20 years. She has held various positions within the property departments of General Electric, BT Group and CLS Holdings. She holds a degree in property valuation and nance from City University and is the daughter of Mr Sten Mörtstedt. Anna is also on the board of directors of the Sten Mortstedt Family and Charity Trust.

Scientific Advisory Board

Professor Anthony E. Lang
Movement Disorders Centre
Toronto Western Hospital

Professor Irene Litvan
Tasch Endowed Professor in Parkinson's Disease Research
Director of the Movement Disorder Center
University of California, San Diego

Professor Thomas Perlmann
Karolinska Institutet Stockholm

Professor Michael A. Schwarzschild
Harvard Medical School, Boston

Professor Per Svenningsson
Karolinska Institutet Stockholm

Professor Håkan Widner
Lund University

Professor Stefan Lorenzl
Ludwig Maximilian University of Munich

Management team

Samuel Svensson, CEO
Samuel Svensson PhD (Pharmacology) has been working for more than 10 years at Neuroscience AstraZeneca R&D Södertälje, Sweden responsible for the development of the amyloid selective PET radiotracer 18F-AZD4694 recently acquired by Navidae Biopharmaceuticals. He is a cofounder and Senior Principal Scientist at the Alzecure Research foundation and chairman at BioPercept AB. Samuel Svensson is an adjunct Professor in Pharmacology at Div for Drug Research, Linkoping University.